Novo Nordisk

Continent’s top firms drove most of European equity gains last year

Pan-European Stoxx 600 extends gains and hit a fresh record high, rising 1 per cent

Drug maker trades on multiples unheard of in pharma sector over anticipated sales of weight loss drug

Stocktake: Europe’s most valuable company last week exceeded a market value of $500bn after reporting better-than-expected earnings

The drug maker has struggled to keep up with demand for both Wegovy and Ozempic

From flight cancellation misery and forfeited pay to corporation tax hauls and obesity drug bonanzas, everything in 2023 had either a value or a cost

News of new factory comes after Danish group announced in December the purchase of drug manufacturing plant in Athlone in order to keep up with demand for weight-loss drugs

Pharmaceutical giant suffers a post-Covid-19 hangover as demand for pandemic vaccines and medicines falls sharply

Danish weight loss and diabetes specialist is looking to develop a tablet form of its blockbuster obesity treatments

Proposals would lower time period a company has protection over research behind drugs they develop

Correspondence between health officials details 'high level of concern' about obesity drug shortages

Helge Lund has sought to reassure investors following Looney’s abrupt departure

Company boosted by trial results showing weight loss drug also cuts risk of heart attack by 20%

Planet Business: Pre-Swift concert film hits, Qantas’s under-fire chairman, and the ascent of Novo Nordisk

Novo Nordisk profits surging due to huge demand for obesity drugs Ozempic and Wegovy

Website advertising Ozempic for sale online falsely using address of north Dublin pharmacy

Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest pharma shake-up in decades

Sportswear companies among fallers after downbeat profit forecast from US retailer Foot Locker

Danish drugmaker pushing for US and EU approval but has struggled to meet demand for its Ozempic and Wegovy drugs

French luxury group’s share price rises as sector continues to benefit from China rebound

Demand for diabetes drug Ozempic, also used off label for weight loss, also fuels near doubling of sales and profit expectations

US shares fall on inflation worries

Iseq closes slightly higher with house builders Cairn and Glenveagh in focus

Travel stocks fell 1 per cent, but were above their intra-day lows touched earlier in session

Obesity drug resulted in weight loss of more than 10%, research shows

Fears about falling Chinese demand send iron ore prices plunging in London

Drugmaker, which spun out of Elan is selling PRX004 so it can focus on other therapies

Those who got the drug in a trial lost close to 15% of their body weight, compared with 2.4% among those receiving the placebo

Positive sentiment spills over from Asian markets

Iseq lags European peers, but closes marginally ahead

Iseq fell 1.74% as banks take a hammering

Novo Nordisk wary of pandemic’s impact on patient diagnosis and ability to pay

But Tesla and Airbus among the companies to fall on concerns about China outbreak

In Dublin, AIB jumps on news of another sell-off of bad loans

Netflix takes a battering as analysts queries international subscriber growth

Test flight is first time the technology has been used in management of diabetes

Iseq performed in line with European peers, rose 0.34%

Drug failure pushes pharma giant to lower forecasts for 2019

Good day for Irish shares with Iseq overall index rising 1.08%

Investors both sides of the Atlantic take a cautiously optimistic view of US-China talks